Maintenance‐phase treatments involved MMF or RTX, with 9 patients (28.1%) receiving MMF alone or with OS, 5 patients (15.6%) receiving RTX infusion (periodic single dose of 375 mg/m2 of body surface area; reinfusion will be given when CD19+ B‐cell counts of total lymphocytes reach 1%) alone or with OS, and 5 patients (15.6%) initially receiving MMF without marked improvement, converting to RTX infusion, then 3 patients with epilepsy experiencing a reduction in seizure frequency and less severity in seizure types, and one patient with limbic encephalitis achieving complete remission. Here, CD19 is linked to epilepsy.